Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Nowakowski, Grzegorz S  [Clear All Filters]
2024
Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024.
2023
Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023.
Desai SH, Spinner MA, Evens AM, Sýkorová A, Bachanova V, Goyal G, Kahl BS, Dorritie KA, Azzi J, Kenkre VP, et al. Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. Blood Adv. 2023.
Nowakowski GS, Yoon DHyun, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large . Ann Hematol. 2023.
Belada D, Kopeckova K, Burgues JMiguel Ber, Stevens D, André M, Persona EPerez, Pichler P, Staber PB, Trneny M, Duell J, et al. Safety and efficacy of tafasitamab ± lenalidomide added to first-line R‑CHOP for DLBCL: Phase 1b First-MIND study. Blood. 2023.
2022
N Bennani N, Kim HJin, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022;10(6).
Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022.